Login to Your Account



Financings Roundup

Tarsa Pads Coffers Ahead of NDA Filing for Oral Calcitonin

By Jennifer Boggs


Wednesday, July 13, 2011
Three months after reporting positive top-line data from its Phase III study of oral calcitonin in postmenopausal osteoporosis patients, Tarsa Therapeutics Inc. disclosed a $24.5 million financing round that should get the Philadelphia-based firm through a new drug application (NDA) filing later this year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription